Comments on the discordant recommendations for the use of symptomatic slow-acting drugs in knee osteoarthritis

Despite the near concurrent publication by influential scientific organizations, there are important differences in interpretation of the evidence base and the conclusions derived from the recent Osteoarthritis Research Society International (OARSI) guidelines for the management of knee osteoarthritis, the American College of Rheumatology (ACR) guidelines (concerning also hip and hand osteoarthritis) and the algorithm recommendations by the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO). This is particularly evident for the drug class of symptomatic slow-acting drugs in osteoarthritis. In this paper, we highlight these differences and try to understand where they derive from, proposing an evidence-based interpretation.

Palavras-chave

Chondroitin Glucosamine Hyaluronic acid Osteoarthritis Symptomatic slow-acting drugs in osteoarthritis General Medicine

URI

http://hdl.handle.net/10362/142323

DOI

10.1185/03007995.2015.1027183

Coleções

NMS: CEDOC - Artigos em revista internacional com arbitragem científica

Métricas Alternativas

Ver registo completo